News & Updates

Show Multimedia Only

First-line durvalumab plus tremelimumab safe to use in unresectable HCC

05 Sep 2025 by

The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.

First-line durvalumab plus tremelimumab safe to use in unresectable HCC

05 Sep 2025

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025 by

Combination treatment with the oral, highly selective FGFR4 inhibitor irpagratinib plus atezolizumab has shown promising efficacy in patients with untreated or immune checkpoint inhibitor (ICI)-exposed hepatocellular carcinoma (HCC) with fibroblast growth factor 19 overexpression (FGF19+), while being safe and well tolerated, according to the updated results of the phase II ABSK-011-201 study.

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025

Semaglutide 2.4 mg gets US FDA approval for MASH

01 Sep 2025 by

Subcutaneous (SC) semaglutide 2.4 mg QW is recently granted accelerated approval by the US FDA for treatment of metabolic dysfunction–associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.

Semaglutide 2.4 mg gets US FDA approval for MASH

01 Sep 2025

Breath analyser shows promise for sniffing out high-risk MASLD

29 Aug 2025 by

Exhaled breath analysis using the so-called eNose technology not only accurately identifies individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) but also pinpoints those at high risk of accelerated disease progression.

Breath analyser shows promise for sniffing out high-risk MASLD

29 Aug 2025

Icosabutate shows potential as treatment for MASH

24 Aug 2025

Treatment with icosabutate is associated with encouraging fibrosis and noninvasive biomarker data, lending support for its development in patients with metabolic dysfunction-associated steatohepatitis (MASH), reports a study.

Icosabutate shows potential as treatment for MASH

24 Aug 2025

Bile acid accumulation predicts liver injury after portoenterostomy

23 Aug 2025

The accumulation of altered serum bile acids appears to increase the risk of liver disease progression and result in poorer transplant-free survival following Kasai portoenterostomy (KPE) for biliary atresia (BA), a study has shown.

Bile acid accumulation predicts liver injury after portoenterostomy

23 Aug 2025

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

15 Aug 2025

In patients with cirrhosis and upper gastrointestinal (GI) bleeds, mortality outcome does not differ between shorter and longer antibiotic prophylaxis durations, according to a systematic review and Bayesian meta-analysis.

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

15 Aug 2025

MASLD severity tied to poor cognitive function, HRQoL in patients with obesity

11 Aug 2025

Greater severity in metabolic dysfunction-associated steatotic liver disease (MASLD) may impair cognitive function and health-related quality of life (HRQoL) in patients with overweight or obesity, suggests a study.

MASLD severity tied to poor cognitive function, HRQoL in patients with obesity

11 Aug 2025

HBV vaccination, HIV PEP compliance low among young sexual assault victims

11 Aug 2025 by

Many paediatric sexual assault victims do not receive hepatitis B virus (HBV) postexposure vaccination and have low compliance to HIV postexposure prophylaxis (PEP), reveals a study in Singapore.

HBV vaccination, HIV PEP compliance low among young sexual assault victims

11 Aug 2025

Healthy behaviours may prevent death in cirrhosis patients

05 Aug 2025

Keeping a healthy lifestyle such as having a balanced diet, regular exercise, and quality sleep may provide survival benefits to patients with cirrhosis, suggests a study.

Healthy behaviours may prevent death in cirrhosis patients

05 Aug 2025

News & Updates

Showing Hepatology articles

Showing

Specialty:

First-line durvalumab plus tremelimumab safe to use in unresectable HCC

First-line durvalumab plus tremelimumab safe to use in unresectable HCC

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

Semaglutide 2.4 mg gets US FDA approval for MASH

Semaglutide 2.4 mg gets US FDA approval for MASH

Breath analyser shows promise for sniffing out high-risk MASLD

Breath analyser shows promise for sniffing out high-risk MASLD

Icosabutate shows potential as treatment for MASH

Icosabutate shows potential as treatment for MASH

Bile acid accumulation predicts liver injury after portoenterostomy

Bile acid accumulation predicts liver injury after portoenterostomy

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

No mortality benefit with longer antibiotic prophylaxis durations in cirrhosis, upper GI bleeds

MASLD severity tied to poor cognitive function, HRQoL in patients with obesity

MASLD severity tied to poor cognitive function, HRQoL in patients with obesity

HBV vaccination, HIV PEP compliance low among young sexual assault victims

HBV vaccination, HIV PEP compliance low among young sexual assault victims

Healthy behaviours may prevent death in cirrhosis patients

Healthy behaviours may prevent death in cirrhosis patients